Seaport Therapeutics (SPTX) Stock Price, News & Analysis

Company Overview

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.

Key Stats

• Today's Range: $23.63 to $25.00
• 50-Day Range: $18.23 to $27.84
• 52-Week Range: $14.85 to $28.38
• Volume: 104,337 shs
• Average Volume: 125,018 shs
• Market Capitalization: $1.33 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.33
• Consensus Rating: Hold

Seaport Therapeutics Stock Analysis - MarketRank™

Seaport Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 271st out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Seaport Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on no strong buy ratings, 6 buy ratings, 3 hold ratings, and 2 sell ratings.

Upside Potential

Seaport Therapeutics has a consensus price target of $37.33, representing about 50.2% upside from its current price of $24.86.

Amount of Analyst Coverage

Seaport Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Seaport Therapeutics are expected to grow in the coming year, from ($4.60) to ($2.95) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Seaport Therapeutics is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Seaport Therapeutics is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Seaport Therapeutics has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.63% of the float of Seaport Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Seaport Therapeutics has a short interest ratio ("days to cover") of 25.13, which indicates bearish sentiment.

Change versus previous month

Short interest in Seaport Therapeutics has recently increased by 9.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Seaport Therapeutics does not currently pay a dividend.

Dividend Growth

Seaport Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.22

News Sentiment

Seaport Therapeutics has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Seaport Therapeutics this week, compared to 2 articles on an average week.

Search Interest

11 people have searched for SPTX on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Seaport Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $235,820.00 in company stock, which represents 0.0177% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Seaport Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $235,820.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

Seaport Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 9/06/2026
• Citigroup’s Biopharma Back to School Summit 2026: 9/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SPTX
• CIK: 2042347
• Web: www.seaporttx.com
• Phone: 617-807-4062
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Seaport Therapeutics: $37.33
• High Price Target: $50.00
• Low Price Target: $30.00
• Potential Upside/Downside: +50.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.36
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.00
• Quick Ratio: 18.00

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.89 per share
• Price / Book: 3.15

Miscellaneous

• Outstanding Shares: 53,530,000
• Free Float: N/A
• Market Cap: $1.33 billion
• Optionable: N/A
• Beta: N/A